€7 Million to Generate First in Class Anti-TACA Antibodies for Cancer Treatment
26-Sep-2019 -
Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, announced that it has successfully secured €7 million in seed funding. The funding round involves a syndicate of leading European life science and ...
antibodies
cancer therapy
power plants
+2